Lifting the Veil on Myeloma Bone Disease
Health and Metabolism · 2025
DOI: 10.53941/hm.2025.100005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health and Metabolism, 2025. Verfasst von Rui Chen und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Multiple myeloma (MM), a hematological malignancy originating from malignant plasma cells in the bone marrow, predominantly affects the elderly, and its incidence is on the rise. It is currently the second most common hematological malignancy. Osteolytic bone disease, a severe complication detected in nearly 80% of myeloma patients, affects the entire skeletal system, particularly the skull, spine, pelvis, and long bones of the limbs. This condition causes pathological fractures, severe bone pain, spinal cord compression, and hypercalcemia. The management of bone damage in myeloma patients presents numerous challenges, with current clinical treatments primarily relying on bisphosphonates and anti-RANKL monoclonal antibodies (Denosumab). This review summarizes recent advancements in research on myeloma and bone damage, focusing on the complex interactions between myeloma cells and various other cell types that affect the skeleton. It also discusses the challenges encountered in bone damage research, highlighting potential future research directions and proposing therapeutic strategies.
Zitieren
APA
Chen, R., Liu, R., & Liu, H. (2025). Lifting the Veil on Myeloma Bone Disease. Health and Metabolism. https://doi.org/10.53941/hm.2025.100005
Vancouver
Chen R, Liu R, Liu H. Lifting the Veil on Myeloma Bone Disease. Health and Metabolism. 2025. doi:10.53941/hm.2025.100005
BibTeX
@article{Chen2025,
author = {Chen, Rui and Liu, Rui and Liu, Huan},
title = {Lifting the Veil on Myeloma Bone Disease},
journal = {Health and Metabolism},
year = {2025},
doi = {10.53941/hm.2025.100005}
}
EUVIMED